Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2025-08-28 Regulatory Filings
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Percheron Receives $1.43m R&D Tax Incentive Rebate 1
Regulatory Filings Classification · 95% confidence The document is an ASX announcement about Percheron Therapeutics receiving a $1.43 million R&D tax incentive rebate for the 2025 financial year. It provides information on the rebate and how the funds will be used, but it does not contain any financial statements, detailed financial results, or comprehensive report data. The document is short (1894 characters) and serves as an update or announcement rather than a full report. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is not a regulatory certification or officer attestation. The content is best classified as a general regulatory announcement about a financial incentive received, which fits the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other specific categories.
2025-08-28 English
Appendix 4E and Annual Report 57 pages 4.2MB
Regulatory Filings
2025-08-27 English
Appendix 4G and Corporate Governance Statement 28 pages 770.0KB
Governance Information Classification · 100% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a detailed key to corporate governance disclosures, indicating compliance with ASX Corporate Governance Council recommendations for the financial year ended 30 June 2025. The document is not the corporate governance statement itself but a verification and key to disclosures, as required to be lodged with ASX alongside the annual report. It does not contain financial statements or management discussion but focuses on governance disclosures and compliance. The document length is 15,000 characters, indicating a substantive filing rather than a brief announcement. Given the content and purpose, this document fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-08-27 English
Notice of date of AGM and other relevant dates 1 pa
AGM Information Classification · 95% confidence The document is an ASX announcement titled 'NOTICE OF DATE OF ANNUAL GENERAL MEETING AND OTHER RELEVANT DATES'. It provides the date and time of the upcoming AGM, the date of dispatch for the Notice of Meeting, and other procedural details related to the AGM. It also references the availability of the Annual Report and Appendix 4E but does not contain the report itself. The document is relatively short (2540 characters) and serves as a notification rather than the full AGM materials or the Annual Report. Therefore, it fits the category of AGM Information (AGM-R), which includes presentations and materials shared during or about the AGM, or announcements related to the AGM. Given the content focuses on the AGM date and related procedural information, the best classification is AGM Information (AGM-R).
2025-08-27 English
New Preclinical Data Reported for HMBD-002 in Breast Cancer 3 pages 155.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Percheron Therapeutics Limited dated 6 August 2025. It discusses new preclinical data published by researchers at the University of Texas regarding the activity of the drug HMBD-002 in triple-negative breast cancer. The announcement summarizes key points of the research, background on the study, and implications for future development. It also mentions the expectation of releasing Phase I clinical trial data in Q4 CY2025. The document is a corporate announcement sharing scientific and clinical development updates rather than a formal financial report, earnings release, or regulatory filing. It does not contain financial statements, voting results, management changes, or legal proceedings. It is not a report publication announcement since it contains substantive content about the research findings and company plans. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a general category for miscellaneous corporate announcements that do not fit other specific filing types.
2025-08-05 English
Quarterly Activities Report and Appendix 4C 10 pages 480.4KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement titled 'Quarterly Activities Report and Appendix 4C' for the quarter ended 30 June 2025. It provides a detailed update on the company's activities during the quarter, including licensing agreements, clinical trial progress, financial position, and cash flow statements. The inclusion of Appendix 4C, which is a quarterly cash flow report required by ASX Listing Rule 4.7B, confirms this is a quarterly report. The document contains substantive financial data and analysis for the quarter, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q4 2025
2025-07-30 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.